Side-by-side comparison of AI visibility scores, market position, and capabilities
Gurugram India YC W20 digital therapeutics for diabetes/PCOD/thyroid/hypertension reversal serving 150M Indian chronic disease patients; $12.9M total (Accel/General Catalyst Series A 2021 + ₹50Cr pre-Series B 2023) competing with Twin Health.
Breathe Well-being is a Gurugram, India-based digital therapeutics platform — backed by Y Combinator (W20) with $12.9 million in total funding including a ₹50 crore ($6 million) pre-Series B in 2023 and a $5.5 million Series A in August 2021 led by Accel with General Catalyst, 3one4 Capital, and Scott Shleifer — providing Indians with clinically validated digital programs for reversing and managing Type 2 diabetes, PCOD (polycystic ovarian disease), thyroid disorders, and hypertension through structured weight loss programs combining personalized nutrition coaching, behavioral change support, and continuous glucose monitoring. Founded in 2020 with a mission to help 1 million Indians reverse Type 2 diabetes by 2025, Breathe targets India's 150 million chronic lifestyle disease patients.
Diversified healthcare company with $20-22B revenue; FreeStyle Libre CGM, cardiovascular devices, and diagnostics across medical devices, nutrition, and pharma.
Abbott Laboratories is a diversified global healthcare company operating across diagnostics, medical devices, nutritional products, and established pharmaceuticals in over 160 countries. Founded in 1888 by Dr. Wallace Calvin Abbott in Chicago, Illinois and listed on the NYSE, Abbott generates approximately $20-22 billion in annual revenue and employs over 100,000 people globally. The company's portfolio spans four major segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals.
Breathe Well-being vs
Abbott Laboratories vs
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.